Preclinical Pharmacokinetics and Bioavailability of Oxypeucedanin in Rats after Single Intravenous and Oral Administration

  • Molecules. 2022 Jun 2;27(11):3570. doi: 10.3390/molecules27113570.
Ming-Cong Zheng  1  2 Wen-Ting Tang  1 Lu-Lu Yu  1 Xun-Jia Qian  1 Jie Ren  1 Jie-Jia Li  3 Wei-Wei Rong  1 Jun-Xu Li  1 Qing Zhu  1  2
Affiliations
  • 1. School of Pharmacy, Nantong University, Nantong 226001, China.
  • 2. Provincial Key Laboratory of Inflammation and Molecular Drug Target, Nantong 226001, China.
  • 3. State Key Laboratory for the Quality Research of Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China.
Abstract

Oxypeucedanin, a furanocoumarin extracted from many traditional Chinese herbal medicines, has a variety of pharmacological effects. However, the independent pharmacokinetic characteristics and bioavailability of this compound remains elusive. In this study, a rapid, sensitive, and selective method using ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) was developed for evaluating the intravenous and oral pharmacokinetics of oxypeucedanin. After intravenous administration of oxypeucedanin (2.5, 5, and 10 mg/kg), and intragastric administration of oxypeucedanin (20 mg/kg), blood samples were collected periodically from the tail vein. The plasma concentration-time curves were plotted, and the pharmacokinetic parameters were calculated using a non-compartmental model analysis. After intravenous administration of oxypeucedanin (single dosing at 2.5, 5, and 10 mg/kg) to rats, the pharmacokinetics fit the linear kinetics characteristics, which showed that some parameters including average elimination half-life (T1/2Z of 0.61~0.66 h), mean residence time (MRT of 0.62~0.80 h), apparent volume of distribution (VZ of 4.98~7.50 L/kg), and systemic clearance (CLZ of 5.64~8.55 L/kg/h) are dose-independent and the area under concentration-time curve (AUC) increased in a dose-proportional manner. Single oral administration of oxypeucedanin (20 mg/kg) showed poor and slow absorption with the mean time to reach the peak concentration (Tmax) of 3.38 h, MRT of 5.86 h, T1/2Z of 2.94 h, and a mean absolute bioavailability of 10.26% in rats. These results provide critical information for a better understanding of the pharmacological effect of oxypeucedanin, which will facilitate its research and development.

Keywords
UPLC/MS/MS; bioavailability; oxypeucedanin; pharmacokinetics; rats.
Products